Daniel C Cho Selected Research

Daniel C Cho Research Topics

Disease

23	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 02/2009
17	Neoplasms (Cancer) 03/2024 - 07/2010
4	Disease Progression 12/2023 - 10/2011
3	Carcinoma (Carcinomatosis) 01/2023 - 11/2020
3	Melanoma (Melanoma, Malignant) 10/2021 - 01/2008
3	Neoplasm Metastasis (Metastasis) 08/2014 - 11/2011
2	Fatigue 12/2023 - 01/2018
2	Anemia 12/2023 - 11/2011
2	Glioma (Gliomas) 01/2023 - 01/2022
2	Pneumonia (Pneumonitis) 01/2021 - 07/2012
2	Kidney Neoplasms (Kidney Cancer) 08/2011 - 02/2009
1	Exanthema (Rash) 12/2023
1	Diarrhea 12/2023
1	Pruritus (Itching) 12/2023
1	Fever (Fevers) 12/2023
1	Nausea 12/2023
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2023
1	Anaplastic Thyroid Carcinoma 01/2023
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2023
1	Adenocarcinoma 01/2023
1	Hairy Cell Leukemia 01/2023
1	Multiple Myeloma 01/2023
1	Myocarditis (Carditis) 01/2023
1	Pleural Effusion (Pleural Effusions) 01/2023
1	Urologic Neoplasms (Urological Cancer) 10/2022
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Syncope (Fainting) 01/2022
1	Dyspnea (Shortness of Breath) 01/2021
1	Colitis 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020
1	Hypertension (High Blood Pressure) 01/2018
1	Hypothyroidism 01/2018
1	Cardiac Tamponade 07/2013
1	Endometrial Neoplasms (Endometrial Cancer) 04/2013

Drug/Important Bio-Agent (IBA)

7	pembrolizumabIBA 03/2024 - 01/2018
7	NivolumabIBA 10/2022 - 01/2020
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 02/2009
4	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2013
4	bempegaldesleukinIBA 10/2022 - 01/2020
4	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 07/2019 - 07/2010
3	IpilimumabIBA 01/2022 - 11/2020
3	Interleukin-2 (IL2)IBA 10/2021 - 02/2009
3	Axitinib (AG 013736)IBA 01/2021 - 01/2018
3	Sunitinib (Sutent)FDA Link 01/2021 - 10/2011
3	TOR Serine-Threonine KinasesIBA 08/2014 - 07/2012
3	MTOR InhibitorsIBA 12/2012 - 07/2011
2	parsaclisibIBA 03/2024 - 12/2023
2	itacitinibIBA 03/2024 - 12/2023
2	dabrafenibIBA 01/2023 - 01/2022
2	trametinibIBA 01/2023 - 01/2022
2	CytokinesIBA 01/2023 - 08/2011
2	Monoclonal AntibodiesIBA 01/2023 - 10/2022
2	ProdrugsIBA 10/2022 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2018
2	dactolisibIBA 07/2019 - 07/2010
2	Sirolimus (Rapamycin)FDA Link 07/2019 - 07/2010
2	perifosineIBA 02/2013 - 12/2012
2	temsirolimus FDA Link 06/2012 - 07/2011
2	Sorafenib (BAY 43-9006)FDA Link 11/2011 - 01/2008
1	Proto-Oncogene Proteins B-rafIBA 01/2023
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023
1	TroponinIBA 01/2023
1	Immunoglobulin G (IgG)IBA 01/2023
1	Cisplatin (Platino)FDA LinkGeneric 10/2022
1	Immunoglobulins (Immunoglobulin)IBA 10/2022
1	Lipase (Acid Lipase)FDA Link 01/2022
1	varlilumabIBA 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 01/2021
1	cobimetinibIBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	ipatasertibIBA 01/2021
1	LipidsIBA 01/2019
1	Alanine Transaminase (SGPT)IBA 01/2018
1	XL147IBA 07/2017
1	seribantumabIBA 07/2017
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 08/2014
1	CamptothecinIBA 06/2014
1	TLC 388IBA 06/2014
1	LactonesIBA 06/2014
1	VemurafenibIBA 07/2013
1	Proteins (Proteins, Gene)FDA Link 04/2013
1	Messenger RNA (mRNA)IBA 04/2013
1	KinesinsIBA 04/2013
1	Small Interfering RNA (siRNA)IBA 04/2013
1	Lipid NanoparticlesIBA 04/2013
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2013
1	Tyrosine Kinase InhibitorsIBA 01/2013
1	Phosphatidylinositols (Phosphatidylinositol)IBA 12/2012
1	CholesterolIBA 06/2012
1	Hemoglobins (Hemoglobin)IBA 11/2011
1	Bevacizumab (Avastin)FDA Link 11/2011
1	Gemcitabine FDA Link 10/2011
1	Angiogenesis InhibitorsIBA 08/2011

Therapy/Procedure

15	Therapeutics 12/2023 - 02/2009
3	Drug Therapy (Chemotherapy) 10/2022 - 06/2014
2	Immunotherapy 01/2020 - 01/2019
1	Chemoradiotherapy 01/2022
1	Radiotherapy 01/2022
1	RNAi Therapeutics 04/2013